drugset / Trial / NCT05687279

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

NCT05687279

Phase 1/2 Completed 80 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary purpose of the study is to assess the shedding, transmission, and genetic stability of the live-attenuated RSVt vaccine after each intranasal vaccination (56 days apart) in infants and toddlers 6 to \< 24 months of age.

Timeline

Start
2023-02-06
Primary completion
2024-12-27
Completion
2024-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject RSVt Vaccine Vaccine Intranasal